Pub Date : 2023-11-16DOI: 10.46610/rtpscr.2023.v05i02.005
Nabamita Basu, S. Rakesh, Rajesh Khanna Kotrike, Giriraj T. Kulkarni, P. V. Babu
The purpose of this research paper is to find out which effective antibacterial substances are in different herbs and their use in acne vulgaris and hyperpigmentation. Herbal gel with four herbs mainly including Azadiracta indica, Hibiscus rosa sinesis, Piper Betle and Aloe barbadensis was formulated with a base gel. Two formulations were prepared and evaluated for pH, dispersibility, detergency, and zone of inhibition. Preliminary phytochemical evaluations of the extracts were performed according to the standard procedures. Later antimicrobial activity of the individual extracts and polyherbal gel was determined by the cup plate method. Phytochemical tests showed the presence of alkaloids, terpenoids, flavonoids, saponins, etc. A strong antibacterial effect was found for a polyherbal gel compared with individual extracts against acne vulgaris. Synergistic interaction between secondary plant metabolites present in each extract might be responsible for the better antimicrobial activity of the polyherbal gel.
{"title":"Formulation and Evaluation of Topical Poly Herbal Gel Consisting of Natural Antimicrobials for the Activity against Acne Vulgaris","authors":"Nabamita Basu, S. Rakesh, Rajesh Khanna Kotrike, Giriraj T. Kulkarni, P. V. Babu","doi":"10.46610/rtpscr.2023.v05i02.005","DOIUrl":"https://doi.org/10.46610/rtpscr.2023.v05i02.005","url":null,"abstract":"The purpose of this research paper is to find out which effective antibacterial substances are in different herbs and their use in acne vulgaris and hyperpigmentation. Herbal gel with four herbs mainly including Azadiracta indica, Hibiscus rosa sinesis, Piper Betle and Aloe barbadensis was formulated with a base gel. Two formulations were prepared and evaluated for pH, dispersibility, detergency, and zone of inhibition. Preliminary phytochemical evaluations of the extracts were performed according to the standard procedures. Later antimicrobial activity of the individual extracts and polyherbal gel was determined by the cup plate method. Phytochemical tests showed the presence of alkaloids, terpenoids, flavonoids, saponins, etc. A strong antibacterial effect was found for a polyherbal gel compared with individual extracts against acne vulgaris. Synergistic interaction between secondary plant metabolites present in each extract might be responsible for the better antimicrobial activity of the polyherbal gel.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"26 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139270480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-18DOI: 10.46610/rtpscr.2023.v05i02.004
S. Prathamesh Ithape, M. Avez, Bharat Dhore, Ramesh R. Pagore
Mental health disorders constitute a significant public health concern, with a growing recognition of the need for integrated, comprehensive approaches to their management and treatment. Pharmacists, as essential members of the healthcare team, have a unique opportunity to contribute to the care of patients with mental health conditions. This review critically examines the multifaceted role of pharmacists in mental health treatment, encompassing their involvement in medication management, patient education, and collaborative care models. Pharmacists play a pivotal role in ensuring the safe and effective use of psychotropic medications, offering expertise in drug selection, dosing, monitoring, and assessing medication adherence. Their involvement in medication reconciliation and management of drug interactions can significantly enhance patient safety and optimize treatment outcomes. Moreover, pharmacists can provide valuable education to patients and caregivers regarding medication adherence, potential side effects, and strategies for managing adverse reactions, thereby promoting medication compliance and improving overall treatment efficacy. Furthermore, the integration of pharmacists within collaborative care teams has demonstrated promising outcomes in the delivery of holistic mental health services. Through their interdisciplinary collaboration, pharmacists facilitate effective communication among healthcare providers, enabling comprehensive treatment planning and the identification of potential pharmacotherapeutic interventions. This collaborative approach fosters a patient- centered care model, emphasizing the importance of individualized treatment plans tailored to each patient’s unique needs and preferences. Additionally, the expanding role of pharmacists in mental health screenings, early intervention initiatives, and community-based support programs serves to promote mental health awareness and reduce the stigma associated with mental illness. By actively engaging with patients and communities, pharmacists contribute to the development of accessible mental health services and resources, thereby fostering a more inclusive and supportive healthcare environment.
{"title":"Pharmacist Involvement in Mental Health Treatment","authors":"S. Prathamesh Ithape, M. Avez, Bharat Dhore, Ramesh R. Pagore","doi":"10.46610/rtpscr.2023.v05i02.004","DOIUrl":"https://doi.org/10.46610/rtpscr.2023.v05i02.004","url":null,"abstract":"Mental health disorders constitute a significant public health concern, with a growing recognition of the need for integrated, comprehensive approaches to their management and treatment. Pharmacists, as essential members of the healthcare team, have a unique opportunity to contribute to the care of patients with mental health conditions. This review critically examines the multifaceted role of pharmacists in mental health treatment, encompassing their involvement in medication management, patient education, and collaborative care models. Pharmacists play a pivotal role in ensuring the safe and effective use of psychotropic medications, offering expertise in drug selection, dosing, monitoring, and assessing medication adherence. Their involvement in medication reconciliation and management of drug interactions can significantly enhance patient safety and optimize treatment outcomes. Moreover, pharmacists can provide valuable education to patients and caregivers regarding medication adherence, potential side effects, and strategies for managing adverse reactions, thereby promoting medication compliance and improving overall treatment efficacy. Furthermore, the integration of pharmacists within collaborative care teams has demonstrated promising outcomes in the delivery of holistic mental health services. Through their interdisciplinary collaboration, pharmacists facilitate effective communication among healthcare providers, enabling comprehensive treatment planning and the identification of potential pharmacotherapeutic interventions. This collaborative approach fosters a patient- centered care model, emphasizing the importance of individualized treatment plans tailored to each patient’s unique needs and preferences. Additionally, the expanding role of pharmacists in mental health screenings, early intervention initiatives, and community-based support programs serves to promote mental health awareness and reduce the stigma associated with mental illness. By actively engaging with patients and communities, pharmacists contribute to the development of accessible mental health services and resources, thereby fostering a more inclusive and supportive healthcare environment.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135883320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-12DOI: 10.46610/rtpscr.2023.v05i02.003
Sree Lakshmi N, Shravan K, Anusha P, Veeresh babu P, Ganga Raju M
Hair is part of the integumentary system and it sits in the hair follicle, which extends into the skin. Hair serves several functions, including protecting the skin and regulating body temperature. Understanding the hair growth cycle is crucial as it is a complex process that involves four distinct phases: Anagen, Catagen, Telogen, and Exogen. These phases are regulated by various factors, such as hormones and genetics. An imbalance in the hair growth cycle can lead to hair loss or Alopecia, Various etiological factors cause hair loss; these include genetic factors, hormonal imbalances, medication, poor diet intake, smoking and environmental factors. In general, alopecia classified into Alopecia areata, Androgenic alopecia, Alopecia universalis, Involutional alopecia, Telogen effluvium, Trichotillomania, and Scarring alopecia. Several animal models have been utilized to study the pathophysiology of Alopecia. These models include mice, and rats similar to human hair and physiology used to study the pathway of Alopecia. Based on the type of Alopecia, animal models differ as androgenic Alopecia occurs due to testosterone sensitivity or due to the Dihydrotestosterone (DHT) hormone, chemotherapy-induced alopecia and alopecia areata by using transgenic animals and C3H/HeJ mice models. The present review provides insight into the anatomy and physiology of the hair and utilizes animal models which can aid in developing new treatment approaches for Alopecia.
{"title":"A Review of Hair Anatomy and Animal Models for Alopecia","authors":"Sree Lakshmi N, Shravan K, Anusha P, Veeresh babu P, Ganga Raju M","doi":"10.46610/rtpscr.2023.v05i02.003","DOIUrl":"https://doi.org/10.46610/rtpscr.2023.v05i02.003","url":null,"abstract":"Hair is part of the integumentary system and it sits in the hair follicle, which extends into the skin. Hair serves several functions, including protecting the skin and regulating body temperature. Understanding the hair growth cycle is crucial as it is a complex process that involves four distinct phases: Anagen, Catagen, Telogen, and Exogen. These phases are regulated by various factors, such as hormones and genetics. An imbalance in the hair growth cycle can lead to hair loss or Alopecia, Various etiological factors cause hair loss; these include genetic factors, hormonal imbalances, medication, poor diet intake, smoking and environmental factors. In general, alopecia classified into Alopecia areata, Androgenic alopecia, Alopecia universalis, Involutional alopecia, Telogen effluvium, Trichotillomania, and Scarring alopecia. Several animal models have been utilized to study the pathophysiology of Alopecia. These models include mice, and rats similar to human hair and physiology used to study the pathway of Alopecia. Based on the type of Alopecia, animal models differ as androgenic Alopecia occurs due to testosterone sensitivity or due to the Dihydrotestosterone (DHT) hormone, chemotherapy-induced alopecia and alopecia areata by using transgenic animals and C3H/HeJ mice models. The present review provides insight into the anatomy and physiology of the hair and utilizes animal models which can aid in developing new treatment approaches for Alopecia.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135970080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-08DOI: 10.46610/rtpscr.2023.v05i02.002
Vivek Kumar Tiwari, M. Reddy
Due to excessive consumption of saturated fats, inactivity, or a sedentary lifestyle, obesity is a widespread health issue that is getting worse around the world. Alzheimer's disease (AD) is caused due to breakdown of amyloid precursor protein to secretase; aggregation and hyperphosphorylation of tau are additional causes that result in NTFs. Over the past couple of decades, cases of dementia, or in more advanced terms, Alzheimer's, have elevated in middle-aged individuals and primarily in the elderly population. We go through the relationship between obesity as well as the pathology of AD in this review. Key elements that are thought to contribute to the development of obesity-induced AD are extensively examined. The impact of a high-calorie food on the brain, the function of insulin, processes through which insulin resistance develops are all examined. Leptin's function in the brain and its resistance, as well as molecular factors including mitochondrial dysfunction, the production of inflammasomes, and the roles of peripheral and central tenderness in the development of obesity-induced AD, are all examined. However, some believe that to be a contentious issue and to determine the specific situation, more investigation is required.
{"title":"A Review on Correlation of Obesity and Alzheimer- Perspective Study","authors":"Vivek Kumar Tiwari, M. Reddy","doi":"10.46610/rtpscr.2023.v05i02.002","DOIUrl":"https://doi.org/10.46610/rtpscr.2023.v05i02.002","url":null,"abstract":"Due to excessive consumption of saturated fats, inactivity, or a sedentary lifestyle, obesity is a widespread health issue that is getting worse around the world. Alzheimer's disease (AD) is caused due to breakdown of amyloid precursor protein to secretase; aggregation and hyperphosphorylation of tau are additional causes that result in NTFs. Over the past couple of decades, cases of dementia, or in more advanced terms, Alzheimer's, have elevated in middle-aged individuals and primarily in the elderly population. We go through the relationship between obesity as well as the pathology of AD in this review. Key elements that are thought to contribute to the development of obesity-induced AD are extensively examined. The impact of a high-calorie food on the brain, the function of insulin, processes through which insulin resistance develops are all examined. Leptin's function in the brain and its resistance, as well as molecular factors including mitochondrial dysfunction, the production of inflammasomes, and the roles of peripheral and central tenderness in the development of obesity-induced AD, are all examined. However, some believe that to be a contentious issue and to determine the specific situation, more investigation is required.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82363766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-19DOI: 10.46610/rtpscr.2023.v05i01.005
L. Munnangi, Koushik Yetukuri
This article highlights the comprehensive review of the prospects and impediments to the innovation of orphan drug development. Orphan medications are used to treat rare diseases. Orphan medication products have been one of the fastest-increasing sectors of drug research. Orphan diseases represent an issue for the world's health sector and a chance to concentrate on innovation. Many nations around the world continue to struggle with rare diseases. Several parties must come up with fresh and innovative solutions to assist the millions of people worldwide who suffer from uncommon diseases. To strategically develop their treatments, pharmaceutical industries concentrate on rare diseases and hinge on novel alliances. To accelerate the research and approval of new drugs, regulatory agencies like US FDA and TGA have developed a wide variety of strategies like financial aid. The process of developing an orphan medicine is the same as for common diseases but requires substantial resources and infrastructure. Several nations including the USA and Australia have implemented orphan drug legislation, which successfully advocated research and development for the creation of novel medication used in the treatment of rare disorders. The purpose of orphan drug regulations was to encourage research and development by providing incentives for the creation of drugs that have the potential to cure millions of individuals suffering from rare illnesses. Prospects related to innovation of orphan drug developments like fee waivers, reimbursements, tax credits and market exclusivity and the majority of the impediments are related to orphan drug pricing patterns, the lack of treatment and diagnosis for rare diseases, regulatory constraints, and the approval process. The individual patient is the major focus of the orphan medication market. For example, the majority of the impediments are related to orphan drug pricing patterns, the lack of treatment and diagnosis for rare diseases, regulatory constraints, and the approval process.
{"title":"A Comprehensive Review on the Prospects and Impediments for the Innovation of Orphan Drug Development in India, Australia and the USA","authors":"L. Munnangi, Koushik Yetukuri","doi":"10.46610/rtpscr.2023.v05i01.005","DOIUrl":"https://doi.org/10.46610/rtpscr.2023.v05i01.005","url":null,"abstract":"This article highlights the comprehensive review of the prospects and impediments to the innovation of orphan drug development. Orphan medications are used to treat rare diseases. Orphan medication products have been one of the fastest-increasing sectors of drug research. Orphan diseases represent an issue for the world's health sector and a chance to concentrate on innovation. Many nations around the world continue to struggle with rare diseases. Several parties must come up with fresh and innovative solutions to assist the millions of people worldwide who suffer from uncommon diseases. To strategically develop their treatments, pharmaceutical industries concentrate on rare diseases and hinge on novel alliances. To accelerate the research and approval of new drugs, regulatory agencies like US FDA and TGA have developed a wide variety of strategies like financial aid. The process of developing an orphan medicine is the same as for common diseases but requires substantial resources and infrastructure. Several nations including the USA and Australia have implemented orphan drug legislation, which successfully advocated research and development for the creation of novel medication used in the treatment of rare disorders. The purpose of orphan drug regulations was to encourage research and development by providing incentives for the creation of drugs that have the potential to cure millions of individuals suffering from rare illnesses. Prospects related to innovation of orphan drug developments like fee waivers, reimbursements, tax credits and market exclusivity and the majority of the impediments are related to orphan drug pricing patterns, the lack of treatment and diagnosis for rare diseases, regulatory constraints, and the approval process. The individual patient is the major focus of the orphan medication market. For example, the majority of the impediments are related to orphan drug pricing patterns, the lack of treatment and diagnosis for rare diseases, regulatory constraints, and the approval process.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90864245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-15DOI: 10.46610/rtpscr.2022.v04i02.005
R. Sethi, F. Khan, Mohammad Foorquan Hashmi, Marlyn Susan George
Objective: A rare case of FMF with atypical presentation of fever attacks lasting 7 days predominantly evident after the war has been described. Usually, the FMF bouts last for 3-4 days but the unusual presentation of our patient led to the initial misdiagnosis of PTSD (Post traumatic stress disorder). Patient and Method: A case of a 38-year-old former Armenian soldier who participated in a 44-day long war with Azerbaijan showing symptoms of recurrent fever, thoracic and abdominal pain predominant only on the left hypochondriac, lumbar and inguinal region. The changes in the laboratory examination were not significant. A wide range of diagnostic tests like X-Ray, CT, and MRI performed all of which were inconclusive. Result: The diagnosis was confirmed after 5 years by positive molecular genetic testing for the MEFV gene. The patient was given colchicine 1 mg/kg/day which reduced the severity and frequency of attacks. Conclusion: The atypical presentation of FMF with prolonged fever lasting up to 7 days, no familial history, post-war trauma, and pain only on the left side led to the differential diagnosis excluding FMF.FMF was suspected when his blood analysis showed acute phase reactants returned to normal after the 7-day attack period. He was started on colchicine therapy and showed a positive response which led to the diagnosis of FMF. The positive MEFV genetic testing confirmed the diagnosis. Clinicians should not exclude the possibility of FMF in patients who do not show the classic fever attack period of 3 to 4 days.
{"title":"A Typical Case of Familial Mediterranean fever in a War Survivor with Post-Traumatic Stress Disorder of Caucasian Descent Treated with Standard Colchicine Therapy","authors":"R. Sethi, F. Khan, Mohammad Foorquan Hashmi, Marlyn Susan George","doi":"10.46610/rtpscr.2022.v04i02.005","DOIUrl":"https://doi.org/10.46610/rtpscr.2022.v04i02.005","url":null,"abstract":"Objective: A rare case of FMF with atypical presentation of fever attacks lasting 7 days predominantly evident after the war has been described. Usually, the FMF bouts last for 3-4 days but the unusual presentation of our patient led to the initial misdiagnosis of PTSD (Post traumatic stress disorder). Patient and Method: A case of a 38-year-old former Armenian soldier who participated in a 44-day long war with Azerbaijan showing symptoms of recurrent fever, thoracic and abdominal pain predominant only on the left hypochondriac, lumbar and inguinal region. The changes in the laboratory examination were not significant. A wide range of diagnostic tests like X-Ray, CT, and MRI performed all of which were inconclusive. Result: The diagnosis was confirmed after 5 years by positive molecular genetic testing for the MEFV gene. The patient was given colchicine 1 mg/kg/day which reduced the severity and frequency of attacks. Conclusion: The atypical presentation of FMF with prolonged fever lasting up to 7 days, no familial history, post-war trauma, and pain only on the left side led to the differential diagnosis excluding FMF.FMF was suspected when his blood analysis showed acute phase reactants returned to normal after the 7-day attack period. He was started on colchicine therapy and showed a positive response which led to the diagnosis of FMF. The positive MEFV genetic testing confirmed the diagnosis. Clinicians should not exclude the possibility of FMF in patients who do not show the classic fever attack period of 3 to 4 days.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"2011 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86329985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charles S Zwerling, Lea Carter, Brandon Lucke-Wold
Traumatic optic neuropathy (TON) is a form of optic nerve damage that while rare in the general population, is commonly associated with traumatic brain injury (TBI). With increasingly high rates of TBI in the military community, our service members and veterans represent a population where traumatic optic neuropathy is prevalent. Parachute jumpers have been identified as a high-risk group for under-reported head injury and therefore many cases of TBI are easily overlooked. With recent insights into the limitations of the veteran's disability exam, we review the current understanding of TON and propose an updated protocol for TON evaluation. We also urge for development of safer helmet design to reduce and prevent further cases of TBI, mTBI, and TON in our military personnel.
{"title":"Current Review of Traumatic Optic Neuropathy and Traumatic Brain Injury among Military Service Members.","authors":"Charles S Zwerling, Lea Carter, Brandon Lucke-Wold","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Traumatic optic neuropathy (TON) is a form of optic nerve damage that while rare in the general population, is commonly associated with traumatic brain injury (TBI). With increasingly high rates of TBI in the military community, our service members and veterans represent a population where traumatic optic neuropathy is prevalent. Parachute jumpers have been identified as a high-risk group for under-reported head injury and therefore many cases of TBI are easily overlooked. With recent insights into the limitations of the veteran's disability exam, we review the current understanding of TON and propose an updated protocol for TON evaluation. We also urge for development of safer helmet design to reduce and prevent further cases of TBI, mTBI, and TON in our military personnel.</p>","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"4 2","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9423907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-20DOI: 10.46610/rtpscr.2022.v04i01.002
Vikrant Dalwal, Priyakul Palia, Shivali Singla, S. Goyal
{"title":"Pharmacological Potential of Qninoline Derivatives","authors":"Vikrant Dalwal, Priyakul Palia, Shivali Singla, S. Goyal","doi":"10.46610/rtpscr.2022.v04i01.002","DOIUrl":"https://doi.org/10.46610/rtpscr.2022.v04i01.002","url":null,"abstract":"","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79679617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-22DOI: 10.46610/rtpscr.2021.v03i02.004
Km. Roshani, Mangla Nand Singh, D. Sasmal, P. Panda, J. Mishra, Reena Singh
Etoricoxib belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). Etoricoxib acts by reducing the pain and swelling (inflammation) in the joints and muscles of people older than 16 years of age and older patients with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout. The present study was aimed to formulate fast dissolving oral films to enhance bioavailability, avoid presystemic metabolism and fast onset of action. The Preformulation studies such as Micromeritics, melting point, partition coefficients, UV spectroscopy, thin layer chromatography, loss on drying were carried out. The fast dissolving oral film was successfully fabricated by solvent casting method. Oral film was fabricated using PVA and PVP polymer. The prepared films were evaluated for Organoleptic evaluations, film weight, thickness, folding endurance, tensile strength, drug content uniformity of films, surface pH, disintegration time and in-vitro dissolution studies and SEM study. The formulation F8 has shown disintegration time of 22±1 seconds and is more promising, showed drug release in phosphate buffer 6.8 pH 86.33% in 10 min. Hence formulation F8 was selected as best formulation. In the stability testing all films stored at elevated temperature showed slight change in pH, other parameters were found to be unchanged.
{"title":"Formulation and Characterization of Fast Dissolving films of Etoricoxib","authors":"Km. Roshani, Mangla Nand Singh, D. Sasmal, P. Panda, J. Mishra, Reena Singh","doi":"10.46610/rtpscr.2021.v03i02.004","DOIUrl":"https://doi.org/10.46610/rtpscr.2021.v03i02.004","url":null,"abstract":"Etoricoxib belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). Etoricoxib acts by reducing the pain and swelling (inflammation) in the joints and muscles of people older than 16 years of age and older patients with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and gout. The present study was aimed to formulate fast dissolving oral films to enhance bioavailability, avoid presystemic metabolism and fast onset of action. The Preformulation studies such as Micromeritics, melting point, partition coefficients, UV spectroscopy, thin layer chromatography, loss on drying were carried out. The fast dissolving oral film was successfully fabricated by solvent casting method. Oral film was fabricated using PVA and PVP polymer. The prepared films were evaluated for Organoleptic evaluations, film weight, thickness, folding endurance, tensile strength, drug content uniformity of films, surface pH, disintegration time and in-vitro dissolution studies and SEM study. The formulation F8 has shown disintegration time of 22±1 seconds and is more promising, showed drug release in phosphate buffer 6.8 pH 86.33% in 10 min. Hence formulation F8 was selected as best formulation. In the stability testing all films stored at elevated temperature showed slight change in pH, other parameters were found to be unchanged.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81596531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-27DOI: 10.46610/rtpscr.2021.v03i02.002
S. Chaudhry, Avisek Dutta
Approximately 30% of the world's population suffers from pain. Pain increases to 50% in those older than 65 years. Multidisciplinary treatment is important parameter in the treatment of both acute and chronic pain. 15% patients generally do not use medications. 35 % patients undergo Non-pharmacological pain therapy which refers to interventions which do not involve the use of medications to treat pain. These methods have virtually no adverse reactions, though have lesser efficacy than pharmacotherapy. Pain experience is reported by 91% to 94% of patients undergoing orthodontic treatment. Low back pain (LBP)-pain experienced in the lumbosacral spinal and paraspinal regions, including the buttocks and upper thigh-is seen in nearly 20% patients.
{"title":"Cutting Edge: Non Pharmacological Management of Pain","authors":"S. Chaudhry, Avisek Dutta","doi":"10.46610/rtpscr.2021.v03i02.002","DOIUrl":"https://doi.org/10.46610/rtpscr.2021.v03i02.002","url":null,"abstract":"Approximately 30% of the world's population suffers from pain. Pain increases to 50% in those older than 65 years. Multidisciplinary treatment is important parameter in the treatment of both acute and chronic pain. 15% patients generally do not use medications. 35 % patients undergo Non-pharmacological pain therapy which refers to interventions which do not involve the use of medications to treat pain. These methods have virtually no adverse reactions, though have lesser efficacy than pharmacotherapy. Pain experience is reported by 91% to 94% of patients undergoing orthodontic treatment. Low back pain (LBP)-pain experienced in the lumbosacral spinal and paraspinal regions, including the buttocks and upper thigh-is seen in nearly 20% patients.","PeriodicalId":74649,"journal":{"name":"Recent trends in pharmaceutical sciences and research","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80678261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：